GX-03 Phase 2 interim results in atopic dermatitis show strong efficacy signals, especially in patients with higher pruritus severity, and a favorable safety profile. Stage 2 is optimized for statistical power and efficiency, with topline results expected Q4 2026.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.